IFP Advisors Inc Buys Shares of 13,700 Sensus Healthcare, Inc. (NASDAQ:SRTS)

IFP Advisors Inc bought a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,700 shares of the company’s stock, valued at approximately $95,000. IFP Advisors Inc owned about 0.08% of Sensus Healthcare as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRTS. Truvestments Capital LLC acquired a new stake in Sensus Healthcare in the 3rd quarter valued at approximately $32,000. XTX Topco Ltd grew its holdings in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares in the last quarter. Sigma Planning Corp acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth approximately $215,000. Ritholtz Wealth Management grew its holdings in shares of Sensus Healthcare by 65.3% during the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock worth $355,000 after purchasing an additional 20,256 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after purchasing an additional 11,525 shares in the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $4.69 on Thursday. The company has a market capitalization of $76.86 million, a PE ratio of 11.73 and a beta of 1.28. Sensus Healthcare, Inc. has a one year low of $2.91 and a one year high of $9.33. The business has a 50 day simple moving average of $6.40 and a 200 day simple moving average of $6.76.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Equities analysts anticipate that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRTS has been the topic of several recent research reports. HC Wainwright lifted their price objective on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Lake Street Capital initiated coverage on Sensus Healthcare in a report on Friday, January 31st. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Maxim Group lifted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.